The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
goldman sachs group reports strong earnings but analysts suggest better investment options
The Goldman Sachs Group, Inc. reported a quarterly EPS of $11.95, exceeding estimates, with revenue of $13.87 billion, up 22.5% year-over-year. Analysts maintain a "Hold" rating, with an average target price of $593.27, while the company declared a quarterly dividend of $3.00 per share.
homeStreet experiences mixed analyst ratings and significant institutional investment changes
Charles Schwab Investment Management Inc. reduced its stake in HomeStreet, Inc. by 31.6%, holding 282,150 shares valued at $3.22 million. Despite a Hold rating from analysts, some believe other stocks are better investments. HomeStreet's stock recently opened at $9.47, with a market cap of $179.18 million and a negative EPS of ($0.27) for the last quarter.
goldman sachs reports strong earnings but analysts favor other stocks
MarketBeat highlights five stocks recommended by top analysts as better buys than The Goldman Sachs Group, which holds a Moderate Buy rating. Goldman Sachs reported a strong quarterly performance with an EPS of $11.95, exceeding estimates, and announced a quarterly dividend of $3.00, yielding 2.21%. Analysts have mixed ratings on the stock, with a consensus target price of $594.27.
analysts favor five stocks over jpmorgan chase amid insider sales
MarketBeat highlights five stocks recommended by top analysts, excluding JPMorgan Chase & Co., which holds a Moderate Buy rating. Analysts predict JPMorgan will report an EPS of 18.1 this year, while insider trading shows significant share sales by executives. Recent analyst reports have adjusted price targets for JPMorgan, with a consensus target of $252.89 and a mix of buy and hold ratings from investment analysts.
analysts recommend five stocks over alvotech despite its buy rating
Market analysts have identified five stocks as top buys, excluding Alvotech, which holds a "Buy" rating with a price target of $18.00 from UBS Group, indicating a potential upside of 40.85%. Alvotech specializes in developing biosimilar medicines for various conditions, with recent institutional investments totaling over $1 million.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.